1 – 36 of 36
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
BioMEL : a translational research biobank of melanocytic lesions and melanoma
(
- Contribution to journal › Article
-
Mark
Molecular patterns of resistance to immune checkpoint blockade in melanoma
(
- Contribution to journal › Article
- 2022
-
Mark
Transcriptomic signatures of tumors undergoing T cell attack
(
- Contribution to journal › Article
-
Mark
DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype
(
- Contribution to journal › Article
- 2021
-
Mark
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
(
- Contribution to journal › Article
-
Mark
Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens
(
- Contribution to journal › Article
-
Mark
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
(
- Contribution to journal › Article
- 2020
-
Mark
Tumor genetic heterogeneity analysis of chronic sun-damaged melanoma
(
- Contribution to journal › Article
-
Mark
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
(
- Contribution to journal › Article
-
Mark
Qualitative analysis of tumor-infiltrating lymphocytes across human tumor types reveals a higher proportion of bystander CD8+ T cells in non-melanoma cancers compared to melanoma
(
- Contribution to journal › Article
-
Mark
CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer
(
- Contribution to journal › Article
- 2019
-
Mark
The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma
(
- Contribution to journal › Article
- 2018
-
Mark
The genetic evolution of melanoma
2018) p.105-114(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2017
-
Mark
NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics
(
- Contribution to journal › Article
-
Mark
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
(
- Contribution to journal › Article
-
Mark
Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNγ signaling
(
- Contribution to journal › Article
- 2016
-
Mark
Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma
(
- Contribution to journal › Article
- 2015
-
Mark
DNA methylation subgroups in melanoma are associated with proliferative and immunological processes.
(
- Contribution to journal › Article
-
Mark
Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy.
(
- Contribution to journal › Article
-
Mark
Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.
(
- Contribution to journal › Article
- 2014
-
Mark
Primary Melanoma Tumors from CDKN2A Mutation Carriers do not Belong to a Distinct Molecular Subclass.
(
- Contribution to journal › Article
-
Mark
Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome.
(
- Contribution to journal › Article
-
Mark
Molecular and genetic diversity in the metastatic process of melanoma.
(
- Contribution to journal › Article
-
Mark
Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study
(
- Contribution to journal › Letter
- 2013
-
Mark
The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
(
- Contribution to journal › Article
- 2012
-
Mark
Genomic analysis of primary and metastatic malignant melanoma
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
(
- Contribution to journal › Article
-
Mark
Molecular profiling reveals low- and high-grade forms of primary melanoma
(
- Contribution to journal › Article
- 2011
-
Mark
Exploring the link between MORF4L1 and risk of breast cancer
(
- Contribution to journal › Article
-
Mark
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers
(
- Contribution to journal › Article
- 2010
-
Mark
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population
(
- Contribution to journal › Article
-
Mark
Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns.
(
- Contribution to journal › Article
-
Mark
Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
(
- Contribution to journal › Article
- 2009
-
Mark
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers
(
- Contribution to journal › Article
- 2007
-
Mark
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A consortium of investigators of modifiers of BRCA1/2 study
(
- Contribution to journal › Article
- 2006
-
Mark
Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies
(
- Contribution to journal › Article